What is the efficacy of long-term treatment of hepatitis B (HBV) (Hep B) with entecavir (ETV) therapy?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

After up to 5 years (240 wk) of continuous entecavir therapy (1.0 mg qDay) for HBeAg-positive patients, 94% of patients had less than 300 copies/mL of HBV DNA, and 80% had normal ALT levels. [78] An additional 23% of patients achieved HBeAg seroconversion, and 1.4% lost HBsAg. Only 1 patient demonstrated treatment resistance with entecavir through 5 years. [78]

In another study, Schiff et al reported that long-term treatment with entecavir (about 6 y of cumulative therapy [range, 267-297 wk]) in nucleoside-naïve chronic hepatitis B patients with advanced fibrosis or cirrhosis resulted in durable virologic suppression, continued histologic improvement, and reversal of fibrosis/cirrhosis. [79] The patients received entecavir for at least 3 years and had evaluable biopsies at baseline and after long-term treatment.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!